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Post-transplant cerebral toxoplasmosis
diagnosed by magnetic resonance imaging
MARCO PICARDI, GENNARO DE ROSA, FRANCESCO DI SALLE,*
LUCA PEZZULLO, ANNAMARIA RAIOLA, BRUNO ROTOLI
Division of Hematology and Department of Radiological
Sciences*, Federico II University Medical School, Naples, Italy
Cerebral toxoplasmosis is a rare late complication in
allogeneic bone marrow transplanted patients. Neu-
roradiological findings may suggest the correct diag-
nosis. We report a patient in whom cerebral magnet-
ic resonance imaging (MRI) showed a lesion charac-
teristic of toxoplasmosis. Anti-toxoplasma treatment
led to clinical and radiological improvement. MRI
seems to be a valid tool for detection and follow-up of
cerebral toxoplasmosis.
Toxoplasmosis is the most common opportunis-
tic infection affecting the central nervous system in
patients with AIDS. Cerebral toxoplasmosis occurs
in about 30% of toxoplasma-seropositive patients
when CD4+ cells fall below 100/mL.1 It has also been
reported in bone marrow transplanted (BMT)
patients.2,3 In principle, a definitive diagnosis of toxo-
plasmosis must be supported by positive serology
and proven by histological evidence of tachyzoites in
a brain lesion. However, in BMT recipients brain
biopsy may not be performable because of throm-
bocytopenia, and serology may be uninformative
because of concurrent immunosuppression. We
report a case of cerebral toxoplasmosis in a patient
with Hodgkin’s disease (HD) who underwent allo-
geneic BMT followed by donor lymphocyte infusions
(DLI) for a post-transplant relapse.
Figure 1. Cerebral MRI. Gradient recalled echo (GRE) sagit-
tal and coronal T1-dependent pre-contrast images (top)
demonstrate a round lesion in the right thalamus, with sev-
eral concentric components (central: high intensity; inter-
mediate: low intensity; peripheral: high intensity) sur-
rounded by a low intensity edema. In the edematous region
a post-contrast (Gadolinium-DTPA) GRE image (bottom,
left) shows the presence of a thin ring-shaped enhance-
ment. In the spin-echo (SE) T2-dependent image (bottom,
right) the center of the lesion appears hypointense.
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HD, nodular sclerosis, stage IV B was diagnosed in
a 22 year-old man in October 1995. After 16 doses
of VEBED (vinblastine, epirubicin, bleomycin, etopo-
side, deflazacort), he achieved partial response. In
June 1996 the patient underwent allogeneic BMT
from his HLA-identical sister. Conditioning was
busulfan-cyclophosphamide; graft versus host dis-
ease (GVHD) prophylaxis was carried out with
cyclosporine; Pneumocystis carinii prophylaxis was per-
formed by aerosolized pentamidine. Engraftment was
documented on day +25. Six months later, with a
bone marrow karyotype XX, mediastinal and liver HD
relapse occurred; the patient was treated by a single
C-MOPP course and two DLI (infused lymphocytes:
0.25 and 0.93108/kg, respectively). Complete remis-
sion (CR) was achieved, but severe cutaneous and
hepatic GVHD occurred, requiring intense immuno-
suppression by cyclosporine and methylpredniso-
lone. A month later fever and neurological symptoms
appeared. ESR and serum LDH were elevated. Brain
CAT scan showed a hypodense right thalamic lesion
of undefined nature; magnetic resonance imaging
(MRI) showed a target-shaped lesion in the right thal-
amic area with a spontaneous hyperintense centre
on T1-weighted images (Figure 1), likely due to hem-
orrhage, and a hypointense centre on T2-weighted
images. A smaller hyperintense lesion was present in
the left lenticula. Brain biopsy could not be per-
formed because of thrombocytopenia. A low titer of
serum anti-toxoplasma IgG was detected. Pyrimetha-
mine-sulfadiazine treatment was started, leading to
marked clinical and neuroradiological improvement
within two months (Figure 2). At present, pyrimetha-
mine-sulfadiazine treatment is continued at lower
doses. HD is still in CR; the patient presents mild
cutaneous and hepatic GVHD, and some neurologi-
cal disturbances persist. 
Toxoplasmosis has to be considered a possible
cause of focal cerebral disease in allogeneic BMT
patients.4 Main risk factors are delayed immunologi-
cal reconstitution and prolonged immunosuppres-
sion needed to control severe forms of GVHD. In
absence of definite histological evidence, a presump-
tive diagnosis of toxoplasmosis can be based on MRI
findings and is confirmed by response to specific anti-
toxoplasma treatment. Peculiar findings at MRI are
multiple round shaped lesions, with ringed or nodu-
lar gadolinium enhancement and mass effect.5 The
lesions are most often localized at the cerebral corti-
cal or corticomedullary junction. A target-shaped
lesion with hypointense centre on T2-weighted images
is considered typical,5 while other findings, such as
the ringed gadolinium enhancement, may also be
found in other diseases.6 In our case, as in others,7
aerosolized pentamidine was an insufficient prophy-
laxis against toxoplasmosis. The intense immuno-
suppression used to control the DLI-induced GVHD
has certainly favored the infectious complication; on
the other hand, DLI treatment may have contributed
to achieve HD remission. To the best of our knowl-
edge, no other case of relapsed HD has been treated
by DLI.8
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Thrombopoietin: a potential T-helper lymphocyte
stimulator. Change in T-lymphocyte composition
and blood cytokine levels in thrombopoietin
cDNA transferred mice
JIAN ZENG ZHAO, YING JIE MEI, ZI KUAN GUO, HUI REN CHEN
Laboratory of Gene Therapy, Center for Clinical Molecular 
Biology, General Hospital of Air Force, PLA, China
The aim of this study was to evaluate the effect of
thrombopoietin (TPO) on T lymphocyte in Balb/c mice
delivered hTPO cDNA with plasmid vector. Both
mature and immature T lymphocytes in central organs
increased, but only the CD4+ subset was preferably
proliferated in circulation. High serum IFN-g was coin-
ciding with the declination of platelet counts, but TNF-
a was positively associated with the platelet count,
while high IL-2 level was similar to the course of TPO
expression. Our data suggested that TPO is a stimu-
lator for T lymphocytes, especially the CD4+ subset. 
Accumulating materials have enlightened the par-
ticipation of thrombopoietin (TPO) in immunologi-
cal processes. TPO stimulates the proliferation of
endothelial cells and enhanced their expression of cell
adhesion molecules.1 It also indirectly induces the
production of interferon-a in vitro.2 We previously
observed macrophage proliferation and endothelial
cell activation in the spleens of TPO gene therapy
mice. Here we have investigated the T lymphocyte
composition and cytokine production of mice with
TPO cDNA delivery.
Female Balb/c mice were delivered with the pcD-
NA3/hTPO plasmid as previously described.4 The
dose was 60 µg plasmid DNA for each mouse. Null-
treated mice as control. Mononuclear cells isolated
from thymocytes, plenocytes, fumer marrow cells and
blood cells were directly stained with FITC conjugat-
ed-anti-mouse CD4 (L3T4) and PE conjugated-anti-
mouse CD8a (Ly-2)(Pharmingen). Samples were
analyzed using a FacStar flow cytometer (Becton
Dickinson). For each sample, 5,000 events were
acquired. Sera collected from 5 mice at set times were
analyzed in duplicate with IFN-g, IL-2 ELISA kits
(Genzyme) and TNF-a kits (Biotinge, China). 
Both mature T lymphocytes (CD4+ or CD8+) and
immature ones (CD4+CD8+) in central and peripheral
immune tissues were affected. They assumed different
characters in the 2nd week. As Figure 1 shows, in mar-
row and spleen, all the three T lymphocyte subsets
increased, while only the immature cells increased in
the thymus. However, CD4+ subset predominantly and
selectively increased in blood.
Serum IFN-g, TNF-a and IL-2 concentrations
began to change early within 24 hr. of gene delivery
(Figure 2). IFN-g peak was 9-12 folds that of the con-
trols and maintained from the 2nd week. Striking peak
TNF-a level was about 120 folds of the controls but
only occurred in the first week. Meanwhile, IL-2 was
high at the most times.
Our data indicated the stimulatory effect of TPO
on T cell production. In this process, T helper subset
was subject to be selectively enhanced, as implied by
the increase in blood CD4+ cells. Elevated immature
but low mature T ratio in the thymus might suggest
a speed-up development. Furthermore, high IFN-g
and IL-2 production implied activation of Th1 and
possibly NK cells in the time. 
Figure 1. T-lymphocyte
frequency alterations.
